ArticleMedicine and pharmacy reports2019
Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin.
Article in Medicine and pharmacy reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2024Trial
- Genomic Insights ofOpen forum infectious diseases · 2026Review
- Smart Antifungal Therapy: Lipase-Responsive Ketoconazole and Atorvastatin Co-loaded Poly є-caprolactone Nanoparticles for Cutaneous Candidiasis.AAPS PharmSciTech · 2025Article
- Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies.Fundamental & clinical pharmacology · 2025Review
- Non-antifungal medications administered during fungal infections drive drug tolerance and resistance inJournal of medical microbiology · 2025Article
- Synthetic Vesicle-Based Drug Delivery Systems for Oral Disease Therapy: Current Applications and Future Directions.Journal of functional biomaterials · 2025Review
- New Ground in Antifungal Discovery and Therapy for Invasive Fungal Infections: Innovations, Challenges, and Future Directions.Journal of fungi (Basel, Switzerland) · 2024Review
- Evaluation of antifungal effect of amphotericin B in comparison with nystatin on Candida species derived from patients undergoing head-and-neck radiotherapy.Dental research journal · 2024Article
- Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses.Infection and drug resistance · 2024Review
- Investigating The Antifungal Activity of Atorvastatin Compared with Nystatin on Oral Candidiasis before and during Head and Neck Radiotherapy.Galen medical journal · 2024Review
- Antifungal effect of atorvastatin in comparison with fluconazole onDental research journal · 2024Article
- Atorvastatin liposomes in a 3D-printed polymer film: a repurposing approach for local treatment of oral candidiasis.Drug delivery and translational research · 2023Article
- Identifying Potential Molecular Targets in Fungi Based on (Dis)Similarities in Binding Site Architecture with Proteins of the Human Pharmacolome.Molecules (Basel, Switzerland) · 2023Article
- Repurposing of atorvastatin emulsomes as a topical antifungal agent.Drug delivery · 2022Article
- In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans.World journal of microbiology & biotechnology · 2021Article
- Drug repurposing strategies in the development of potential antifungal agents.Applied microbiology and biotechnology · 2021Review
- Development of a Solid Dispersion of Nystatin with Maltodextrin as a Carrier Agent: Improvements in Antifungal Efficacy againstPharmaceuticals (Basel, Switzerland) · 2021Article
- Evaluation of the effect of the gold nanoparticles prepared by green chemistry on the treatment of cutaneous candidiasis.Current medical mycology · 2021Article
- Exposure ofJournal of fungi (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsAtorvastatin is a plasma cholesterol-lowering drug which applies antifungal effects by inhibiting the production of yeast cell wall ergostrol. The aim of present study was to investigate in-vitro susceptibility of candida species to atorvastatin, in comparison to nystatin and fluconazole.
methodsMinimum inhibitory concentrations (MIC) and minimum fungicidal concentrations (MFC) were determined using serial dilution. Candida strains isolated from 35 patients receiving cancer chemotherapy in Isfahan, Seyyed-al-Shohada Hospital and analyzed by Kruskal-Wallis and Mann Whitney statistical methods.
resultsCandida isolates included 5 strains,
conclusionThe results showed that all strains were sensitive to atorvastatin and resistant to nystatin and fluconazole. Atorvastatin MIC for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.